Biocon Results

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the treatment of type 2 diabetes.

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA)

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ended March 31, 2025 aided by robust sales across business verticals. The company had reported a net profit of Rs 136 crore in the January-March period of the preceding fiscal. Total revenue rose to Rs 4,454 crore in the latest fourth quarter as compared to Rs 3,966 crore in the year-ago period, Biocon Ltd said in a statement. For the year ended March 31, 2025, the company said its net profit declined to Rs 1,013 crore as compared to Rs 1,022 crore in FY24, it added. Total revenue rose to Rs 16,470 crore in FY25 as compared to Rs 15,621 crore recorded in FY24, the company said. "The Biocon Group ended the year with a strong performance across its businesses," Biocon Group Chairperson Kiran Mazumdar-Shaw said. FY25 has been a year of consolidation and transition, she stated. "We are now on a path of accelerating growth with a commitment to innovation, digita

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Revenue driven by gains from US Oncology and Insulins franchises

Biocon Q4FY24 results: The company board has recommended a final dividend at the rate of 10 per cent i.e. Re. 0.50 per equity share

About a week ago, Syngene International's share price declined by 3 per cent following UBS Global Research stock downgrade to sell

On a sequential basis, the company exhibited a 1.15 per cent increase in revenue along with PAT, which rose 23.8 per cent

Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.

Yesafili aims to treat various visual impairments and age-related macular degeneration

For the entire financial year, the company's net profit saw a decline of 29 per cent to Rs 462.7 crore, as compared to Rs 648.4 crore in 2021-22

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2

Analysts estimate 38 per cent annual growth in earnings during FY20-22

The stock however pared some gains and settled at Rs 513.55, up 15 per cent on BSE